03/06/2023
LAS VEGAS (March 5, 2023) – Chris Buescher had to battle his way through 400 miles at a very windy Las Vegas Motor Speedway Sunday afternoon, ultimately finishing 21st in the NEXLETOL Ford Mustang. After turning the fourth-quickest practice time on Saturday, Buescher put himself 18th on the grid to ...
03/02/2023
Las Vegas I Event Info: Track Info: Las Vegas Motor Speedway, 1.5-mile oval Date: Sunday, March 5 Time: 3:30 p.m. ET Series: NASCAR Cup Series (NCS) Location: Las Vegas, Nevada Format: 267 laps, 400 miles, Stages: 80-85-102 TV: FOX Radio: PRN, SiriusXM NASCAR Radio Weekend Schedule: Saturday: 1:35 p.m. ...
02/27/2023
FONTANA, Calif. (Feb. 26, 2023) – Chris Buescher and the No. 17 team rebounded in a big way Sunday afternoon in the Pala Casino 400 at Auto Club Speedway to finish 13th after an unwelcomed opening stage. “We started off really bad,” Buescher said. “It took us a good amount of time and some big ...
02/20/2023
DAYTONA BEACH, Fla. (Feb. 19, 2023) – Chris Buescher put together a solid start to his 2023 season Sunday afternoon, finishing fourth in the Daytona 500 after earning stage points in each of the first two stages at Daytona International Speedway. “We were up front a lot of the day between both of ...
02/06/2023
LOS ANGELES (Feb. 5, 2023) – The LA Coliseum played host to the NASCAR Cup Series’ exhibition, season-opening race for the second year in a row Sunday afternoon. Despite a strong effort, RFK’s Ford Mustangs did not qualify for the main, 150-lap event. RFK turns its focus to the official start ...
01/19/2023
CONCORD, N.C. (Jan. 19, 2023) – RFK Racing has announced that Castrol®, a partner of the team since 2019, has again expanded its partnership with the championship organization as part of a multi-year renewal. The iconic brand will continue to serve as the team’s official oil partner, while expanding ...
01/11/2023
CONCORD, N.C. (Jan. 11, 2023) – RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) ...
